Combretastatin A1 phosphate

Combretastatin A1 phosphate (Oxi4503) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors[1][2].

Product Specifications

CAS Number

[288847-35-8]

Product Name Alternative

Oxi4503; CA1P; Combretastatin A1 diphosphate

UNSPSC

12352005

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/combretastatin-a1-phosphate.html

Purity

98.00

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC1=C(OP(O)(O)=O)C(OP(O)(O)=O)=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1

Molecular Formula

C18H22O12P2

Molecular Weight

492.31

References & Citations

[1]Patterson DM, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18 (5) :1415-25.|[2]Nguyen L, et al. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. BMC Cancer. 2016 Jul 26;16:533.